Abstracts

Präsentationen zur Hervorhebung des klinischen Nutzens von ZYNLONTA® (Loncastuximab-Tesirin-Lpyl) als Einzelwirkstoff und in Kombination Mündliche Präsentation der ersten Ergebnisse der von einem Prüfarzt initiierten Phase-II-Studie zur…

Mündlicher Kurzvortrag: MCLA-129 in combination with osimertinib in treatment naïve, and after progression on osimertinib, non-small cell lung cancer (MCLA-129 in Kombination mit Osimertinib bei therapienaivem nicht-kleinzelligem…

Nashville, June 29, 2023 (GLOBE NEWSWIRE) -- Ovation® Fertility scientists contributed to four pieces of research accepted for poster presentation at the ESHRE virtual 39th Annual Meeting. The event, hosted by the European Society of…

HINGHAM, Mass., June 16, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) is encouraged by the continued participation and level of enthusiasm being demonstrated by the Key Opinion Leaders (KOL) globally who are using the…

DURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE)…

A pre-clinical data set of AFM13 in combination with Artiva Biotherapeutics Inc.’s allogeneic NK cell AB-101 shows that AFM13 enhances the cytotoxic activity of AB-101 against tumor cells and has been accepted for poster presentationAn…

SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present nine abstracts, including the interim analysis from the ongoing Phase 3 PROTECT…

<!-- Name:DistributionId Value:8846931 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 -->…

<!-- Name:DistributionId Value:8832575 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 -->…

<!-- Name:DistributionId Value:8832568 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 -->…